Viva Biotech Holdings Dirección
Dirección controles de criterios 4/4
El CEO de Viva Biotech Holdings es Chen Cheney Mao , nombrado en Jul 2018, tiene una permanencia de 6.33 años. compensación anual total es CN¥2.39M, compuesta por 60.8% salario y 39.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 15.81% de las acciones de la empresa, por valor de HK$305.19M. La antigüedad media del equipo directivo y de la junta directiva es de 3.6 años y 5.6 años, respectivamente.
Información clave
Chen Cheney Mao
Chief Executive Officer (CEO)
CN¥2.4m
Compensación total
| Porcentaje del salario del CEO | 60.8% |
| Permanencia del CEO | 6.3yrs |
| Participación del CEO | 15.8% |
| Permanencia media de la dirección | 3.6yrs |
| Promedio de permanencia en la Junta Directiva | 5.6yrs |
Actualizaciones recientes de la dirección
Recent updates
Viva Biotech Holdings (HKG:1873) Shares Fly 50% But Investors Aren't Buying For Growth
Oct 14
Investors Don't See Light At End Of Viva Biotech Holdings' (HKG:1873) Tunnel
Aug 30Here's Why Shareholders Should Examine Viva Biotech Holdings' (HKG:1873) CEO Compensation Package More Closely
Jun 19Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?
Jun 14Even With A 25% Surge, Cautious Investors Are Not Rewarding Viva Biotech Holdings' (HKG:1873) Performance Completely
May 03A Look At The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)
Apr 26Positive Sentiment Still Eludes Viva Biotech Holdings (HKG:1873) Following 27% Share Price Slump
Jan 19Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?
Jun 01These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt In A Risky Way
Sep 25Is It Too Late To Consider Buying Viva Biotech Holdings (HKG:1873)?
Jul 11These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt Extensively
Apr 14Is Now The Time To Look At Buying Viva Biotech Holdings (HKG:1873)?
Dec 23Is Viva Biotech Holdings (HKG:1873) Using Too Much Debt?
Nov 06Estimating The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)
Jun 13We Think Viva Biotech Holdings (HKG:1873) Is Taking Some Risk With Its Debt
Apr 17Viva Biotech Holdings (HKG:1873) Shareholders Have Enjoyed A 55% Share Price Gain
Mar 13Need To Know: Viva Biotech Holdings (HKG:1873) Insiders Have Been Selling Shares
Feb 06What Percentage Of Viva Biotech Holdings (HKG:1873) Shares Do Insiders Own?
Jan 02Can You Imagine How Viva Biotech Holdings' (HKG:1873) Shareholders Feel About The 65% Share Price Increase?
Nov 21
Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CN¥318k |
| Mar 31 2024 | n/a | n/a | -CN¥58m |
| Dec 31 2023 | CN¥2m | CN¥1m | -CN¥116m |
| Sep 30 2023 | n/a | n/a | -CN¥276m |
| Jun 30 2023 | n/a | n/a | -CN¥436m |
| Mar 31 2023 | n/a | n/a | -CN¥482m |
| Dec 31 2022 | CN¥3m | CN¥1m | -CN¥528m |
| Sep 30 2022 | n/a | n/a | -CN¥209m |
| Jun 30 2022 | n/a | n/a | CN¥111m |
| Mar 31 2022 | n/a | n/a | CN¥199m |
| Dec 31 2021 | CN¥2m | CN¥1m | CN¥288m |
| Sep 30 2021 | n/a | n/a | CN¥258m |
| Jun 30 2021 | n/a | n/a | CN¥228m |
| Mar 31 2021 | n/a | n/a | -CN¥79m |
| Dec 31 2020 | CN¥1m | CN¥957k | -CN¥387m |
| Sep 30 2020 | n/a | n/a | -CN¥349m |
| Jun 30 2020 | n/a | n/a | -CN¥311m |
| Mar 31 2020 | n/a | n/a | -CN¥23m |
| Dec 31 2019 | CN¥1m | CN¥954k | CN¥266m |
Compensación vs. Mercado: La compensación total ($USD330.70K) de Chen Cheney está en línea con el promedio de empresas de tamaño similar en el mercado Hong Kong ($USD345.78K).
Compensación vs. Ingresos: La compensación de Chen Cheney ha sido consistente con los resultados de la empresa en el último año.
CEO
Chen Cheney Mao (62 yo)
6.3yrs
Permanencia
CN¥2,394,000
Compensación
Dr. Chen Cheney Mao, Ph D has been Chairman of Viva Biotech Holdings since July 03, 2018 and served as Chief Executive Officer of Viva Biotech Holdings since July 03, 2018 until December 1, 2023. He Founde...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & CEO | 6.3yrs | CN¥2.39m | 15.81% HK$ 305.2m | |
| Executive VP & Executive Director | 6.3yrs | CN¥2.68m | 0.81% HK$ 15.7m | |
| Executive Director | less than a year | CN¥3.68m | 0.70% HK$ 13.5m | |
| Chief Financial Officer | less than a year | sin datos | sin datos | |
| Chief Technology Officer | 5.3yrs | sin datos | sin datos | |
| Chief Scientific Officer | 6.3yrs | sin datos | sin datos | |
| Chief Innovation Officer & Head of Viva BioInnovator | no data | sin datos | sin datos | |
| Senior Vice President | no data | sin datos | sin datos | |
| Senior VP & President of Shanghai Langhua Pharmaceutical | no data | sin datos | sin datos | |
| CBO & EVP of Viva Biotech (Shanghai) | no data | sin datos | sin datos | |
| Senior Vice President | 2yrs | sin datos | sin datos | |
| CEO of Viva Biotech (Shanghai) Ltd. | less than a year | sin datos | sin datos |
3.6yrs
Permanencia media
61.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de 1873 se considera experimentado (3.6 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & CEO | 6.3yrs | CN¥2.39m | 15.81% HK$ 305.2m | |
| Executive VP & Executive Director | 15.2yrs | CN¥2.68m | 0.81% HK$ 15.7m | |
| Executive Director | 6.3yrs | CN¥3.68m | 0.70% HK$ 13.5m | |
| Independent Non-Executive Director | 5.6yrs | CN¥225.00k | sin datos | |
| Independent Non-Executive Director | 5.6yrs | CN¥225.00k | sin datos | |
| Independent Non-Executive Director | 5.6yrs | CN¥225.00k | sin datos | |
| Non-Executive Director | 2yrs | CN¥225.00k | sin datos | |
| Non-Executive Director | less than a year | sin datos | 4.01% HK$ 77.4m |
5.6yrs
Permanencia media
61yo
Promedio de edad
Junta con experiencia: La junta directiva de 1873 se considera experimentada (5.6 años de antigüedad promedio).